Evogene Ltd. (EVGN) Financials

EVGN Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 57.7 million 21.9 million
2023-06-30 53.3 million 22.2 million
2023-03-31 49.5 million 21.0 million
2022-12-31 56.1 million 21.3 million

EVGN Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -4.5 million 545000
2023-06-30 -5.2 million 801000
2023-03-31 -6.6 million 418000
2022-12-31 -2.5 million 291000

EVGN Net Income

No data available :(

EVGN Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 37.2 million - 1.2 million
2023-06-30 33.9 million - 1.5 million
2023-03-31 - - 1.6 million
2022-12-31 35.4 million - 1.8 million

EVGN Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 48.9 million
2023-06-30 41.6 million
2023-03-31 41.5 million
2022-12-31 41.2 million

EVGN Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 216000 5.1 million 1.5 million 850000
2023-06-30 124000 5.4 million 1.8 million 928000
2023-03-31 359000 4.8 million 1.5 million 800000
2022-12-31 199000 4.8 million 1.7 million 1.2 million

EVGN Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 3.8 million 511000
2023-06-30 654000 461000
2023-03-31 641000 322000
2022-12-31 660000 364000

EVGN

Price: $0.71

52 week price:
0.45
1.44

Earnings Per Share: -0.52 USD

P/E Ratio: -1.62

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 71621

Ebitda: -8.5 million

Market Capitalization: 38.7 million

Links: